Key Takeaways
- • Bain Capital acquires Vitabiotics for $1.2 billion, securing the UK's leading vitamin and nutraceutical company and its global portfolio including Meyer Organics in India and VB Egypt across Africa.
- • Deal preserves operational continuity with no immediate changes to day-to-day operations; the UK will remain the strategic center for brand, innovation, and category leadership.
- • Investment led by Bain Capital's Asia Private Equity team and supported by the firm's global platform, positioning the acquisition to leverage local market expertise in India and Asia while targeting expansion in MENA and China.
- • Vitabiotics' international footprint expands with planned investments in digital capabilities, e-commerce, international distribution, supply chain resilience, and new product development under Bain Capital's ownership.
- • 55-year-old company founded by Professor Kartar Lalvani has accelerated growth over the past decade under CEO Tej Lalvani through product launches and strategic partnerships, attracting institutional private equity backing for further scaling.
Summary
Bain Capital has agreed to acquire UK-based Vitabiotics, the nation's leading vitamin and nutraceutical company, in a $1.2 billion transaction announced on July 24, 2026. The acquisition encompasses the entire VB Group, including Meyer Organics in India and regional operations across Africa such as VB Egypt, consolidating a diversified global nutraceutical platform under Bain Capital's ownership. The deal size, while undisclosed in the official company statement, is valued at approximately $1.2 billion according to multiple market sources.
The acquisition reflects Bain Capital's strategic focus on leveraging emerging market growth, particularly in Asia. The investment will be led by Bain Capital's Asia Private Equity team and supported by the firm's global platform, enabling the deployment of local market knowledge in India alongside sector expertise and portfolio resources. Bain Capital has committed to utilizing its extensive experience in debt and equity investments to scale Vitabiotics' operations and expand its global reach, with particular emphasis on high-growth markets including the Middle East and North Africa (MENA) region and China.
Vitabiotics, founded in 1971 by scientist and entrepreneur Professor Kartar Lalvani OBE, has undergone significant acceleration over the past decade under the leadership of Group CEO Tej Lalvani. The company has achieved market leadership through strategic product launches and partnerships, positioning it as a preferred acquisition target for institutional investors seeking exposure to the resilient nutraceutical sector. Bain Capital's stewardship will focus on advancing digital capabilities, strengthening e-commerce infrastructure, enhancing international distribution networks, fortifying supply chain resilience, and accelerating new product development.
A key feature of the transaction structure is operational continuity; there will be no immediate changes to day-to-day management, and the UK will remain central to Vitabiotics' brand development, innovation strategy, and category leadership. This stability is intended to preserve customer and partner relationships while enabling the organization to execute on long-term growth initiatives under Bain Capital's financial and strategic support. The deal underscores sustained institutional investor appetite for diversified nutraceutical and wellness platforms with established consumer brand equity and geographic diversification.
The acquisition reflects Bain Capital's strategic focus on leveraging emerging market growth, particularly in Asia. The investment will be led by Bain Capital's Asia Private Equity team and supported by the firm's global platform, enabling the deployment of local market knowledge in India alongside sector expertise and portfolio resources. Bain Capital has committed to utilizing its extensive experience in debt and equity investments to scale Vitabiotics' operations and expand its global reach, with particular emphasis on high-growth markets including the Middle East and North Africa (MENA) region and China.
Vitabiotics, founded in 1971 by scientist and entrepreneur Professor Kartar Lalvani OBE, has undergone significant acceleration over the past decade under the leadership of Group CEO Tej Lalvani. The company has achieved market leadership through strategic product launches and partnerships, positioning it as a preferred acquisition target for institutional investors seeking exposure to the resilient nutraceutical sector. Bain Capital's stewardship will focus on advancing digital capabilities, strengthening e-commerce infrastructure, enhancing international distribution networks, fortifying supply chain resilience, and accelerating new product development.
A key feature of the transaction structure is operational continuity; there will be no immediate changes to day-to-day management, and the UK will remain central to Vitabiotics' brand development, innovation strategy, and category leadership. This stability is intended to preserve customer and partner relationships while enabling the organization to execute on long-term growth initiatives under Bain Capital's financial and strategic support. The deal underscores sustained institutional investor appetite for diversified nutraceutical and wellness platforms with established consumer brand equity and geographic diversification.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.